ARCHIVES

ODAC Member Critical Of Amgen For Price Incentives.

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | March 21, 2008

Download PDF Visit The Full Archive

Related Articles

FDA Says Medicare Policy On ESAs “Consistent With The Available Data.”

October 19, 2007

How NCI Would Apportion New Round Of budget Cuts- 1980 $17 Million, 1981 $42.7 Million

April 11, 1980

Cancer Meetings Listed For Next Three Months

September 20, 1996

FDA Approves Taxotere For Node+ Breast Cancer

August 27, 2004

Ohio State Becomes 18th Comprehensive Center; UCLA Needs Only To Overcome “Minor” Problems

April 16, 1976

In Brief: Reginald Ho Assumes ACS Presidency; Board Calls On NCI To Fully Fund ASSIST Program

November 13, 1992